Drugs / Anti CS6 BSIgG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03040687 | Jan → Apr 2017 | — | Johns Hopkins Bloomberg School of Public Health | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti CS6 BSIgG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03040687 ↗ |
| Modality | Protein / enzyme biologic | “serum-derived bovine immunoglobulins” NCT03040687 ↗ |
| Route | Oral | “orally administered” NCT03040687 ↗ |